DrugPatentWatch Database Preview
Details for Patent: 6,777,423
Which drugs does patent 6,777,423 protect, and when does it expire?
Patent 6,777,423 protects SPIRIVA and is included in one NDA.
Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-one patent family members in forty-six countries.
Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-one patent family members in forty-six countries.
Summary for Patent: 6,777,423
| Title: | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| Abstract: | Crystalline monohydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl) oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4 ]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use. |
| Inventor(s): | Banholzer; Rolf (Stuttgart, DE), Sieger; Peter (Mittelbiberach, DE), Kulinna; Christian (Mainz, DE), Trunk; Michael (Ingelheim, DE), Graulich; Manfred (Waldalgesheim, DE), Specht; Peter (Ober-Hilbersheim, DE), Meissner; Helmut (Ingelheim, DE), Mathes; Andreas (Ockenheim, DE) |
| Assignee: | Boehringer Ingelheim Pharma KG (Ingelheim, DE) |
| Application Number: | 10/354,521 |
|
Patent Claim Types: see list of patent claims | Compound; Process; |
Drugs Protected by US Patent 6,777,423
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | SPIRIVA | tiotropium bromide | POWDER;INHALATION | 021395-001 | Jan 30, 2004 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 6,777,423
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 100 50 621 | Oct 12, 2000 |
Non-Orange Book US Patents Family Members for Patent 6,777,423
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,908,928 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 6,777,423
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1572 | ➤ Sign Up | |||
| Argentina | 034389 | ➤ Sign Up | |||
| Argentina | 068527 | ➤ Sign Up | |||
| Austria | 276253 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
